Is GMDA or DIVO a better dividend investment in 2026?

GMDA currently yields 6116.21% with a 5% 5-year dividend growth rate. DIVO yields 6.62% with 5% growth. The better choice depends on your goal: GMDA offers higher current income.

What is the dividend yield difference between GMDA and DIVO?

GMDA has a forward dividend yield of 6116.21% ($2.00/share annually). DIVO yields 6.62% ($2.91/share annually). The yield gap is 6109.59 percentage points.

Home › Compare › GMDA vs DIVO

GMDA vs DIVO: Dividend Comparison 2026

GMDA yields 6116.21% · DIVO yields 6.62%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 GMDA wins by $442825559222013.81M in total portfolio value

INVESTMENT

TIME HORIZON10 years

GMDA

● Live price

6116.21%

Share price

$0.03

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$442825559222013.81M

Annual income

$429,026,802,483,037,700,000.00

Full GMDA calculator →

DIVO

● Live price

6.62%

Share price

$44.00

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.0K

Annual income

$1,008.47

Full DIVO calculator →

Portfolio growth — GMDA vs DIVO

📍 GMDA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	GMDA	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, GMDA + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

GMDA pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GMDA

Annual income on $10K today (after 15% tax)

$519,877.68/yr

After 10yr DRIP, annual income (after tax)

$364,672,782,110,582,000,000.00/yr

DIVO

Annual income on $10K today (after 15% tax)

$562.67/yr

After 10yr DRIP, annual income (after tax)

$857.20/yr

At 15% tax rate, GMDA beats the other by $364,672,782,110,582,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GMDA + DIVO for your $10,000?

GMDA: 50%DIVO: 50%

100% DIVO50/50100% GMDA

Portfolio after 10yr

$221412779611006.91M

Annual income

$214,513,401,241,518,830,000.00/yr

Blended yield

96.88%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on GMDA right now

GMDA

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-12.9

Piotroski

2/9

DIVO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GMDA buys

DIVO buys

No recent congressional trades found for GMDA or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricGMDADIVO

Forward yield	6116.21% ✓	6.62%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$442825559222013.81M ✓	$31.0K
Annual income after 10y	$429,026,802,483,037,700,000.00 ✓	$1,008.47
Total dividends collected	$441897573176239.63M ✓	$8.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: GMDA vs DIVO ($10,000, DRIP)

Year	GMDA Portfolio	GMDA Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$622,321	$611,620.80	$11,362	$661.96	+$611.0K → GMDA
2	$36,238,251	$35,572,368.18	$12,860	$702.91	+$36.23M → GMDA
3	$1,974,670,479	$1,935,895,550.07	$14,504	$743.56	+$1974.66M → GMDA
4	$100,701,235,006	$98,588,337,593.13	$16,303	$783.73	+$100701.22M → GMDA
5	$4,806,495,889,234	$4,698,745,567,778.20	$18,268	$823.31	+$4806495.87M → GMDA
6	$214,743,265,021,614	$209,600,314,420,132.84	$20,408	$862.17	+$214743265.00M → GMDA
7	$8,981,610,447,341,976	$8,751,835,153,768,850.00	$22,737	$900.20	+$8981610447.32M → GMDA
8	$351,707,912,645,944,000	$342,097,589,467,288,100.00	$25,266	$937.31	+$351707912645.92M → GMDA
9	$12,896,034,335,491,684,000	$12,519,706,868,960,524,000.00	$28,008	$973.42	+$12896034335491.66M → GMDA
10	$442,825,559,222,013,800,000	$429,026,802,483,037,700,000.00	$30,977	$1,008.47	+$442825559222013.81M → GMDA

GMDA vs DIVO: Complete Analysis 2026

GMDA — Stock

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Full GMDA Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this GMDA vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GMDA vs SCHD GMDA vs JEPI GMDA vs O GMDA vs KO GMDA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.